



Etat de la question



J. Andoni URTIZBEREA
Susana QUIJANO-ROY
Bruno EYMARD
Commission RIRE - FILNEMUS





Eléments de contexte

- dernier étage de la fusée européenne Maladies Rares
- projet ancien, cadre légal datant de 2014
- projet porté par la Commission Européenne (UE)
- et s'inscrivant dans les directives soins transfrontaliers
- importants travaux préparatoires (EUCERD)
- objectif d'accès à des soins d'excellence
- dans un contexte d'équité
- mais marche en ordre dispersé
 - entre structures très abouties (PNMR, CRMR, etc.)
 - et des pays où il n'y a rien ou presque
- pour les MNM, on ne part pas de rien



Neuromuscular Disorders

Volume 24, Issue 6, June 2014, Pages 537-545



Workshop report

200th ENMC International Workshop "European Reference Networks: Recommendations and Criteria in the Neuromuscular field", 18–20 October 2013, Naa den, the Netherlands

Teresinha Evangelista^a, ♣ , ■, Baziel van Engelen^b, Kate Bushby^a

Aims of the workshop:

- 1. exchange of knowledge and expertise in processes for the delivery of NMD care
- 2. assessment of existing resources both at national and international level
- 3. identification of gaps which need to be addressed
- decide on a guideline document for the implementation of a ERN in the NMD field



PARTICIPANTS:

A.Ambrosini (IT)

K.Bushby (UK)

M.de Visser (NL)

T.Evangelista (UK)

A.Ferlini (IT)

V.Karcagi (HU)

J.Kirschner (DE)

F.Macchia (FR)

M.Moggio (IT) C.Paradas (ES)

S.Parker (FR)

M.Pohlschmidt (UK)

J.Pouget (FR)

T.Sejersen (SE)

V.Straub (UK)

P.Van den Bergh (BE)

B.Van Engelen (NL)

J. Verschuuren (NL)

JL.Vives Corrons(ES)





Agenda 2015

- webinar ERN (organisé par Newcastle)
- Colloque de Lisbonne (7-8 octobre 2015)
 - grand-messe organisée par Commission Européenne
 - toutes pathologies rares confondues
 - tous types d'acteurs représentés
- travaux de la commission 'Réseaux' FILNEMUS

Agenda 2016

- workshop fin janvier 2016 à Newcastle
 - afin de préparer une application commune
 - à soumettre à l'appel d'offres ERN T1 ou T2 / 2016



Filnemus Filière Neuromusculaire 2ÈME JOURNÉE DE FILNEMUS

Les certitudes

- un appel d'offres ERN aura bien lieu (S1-2016)
- regroupement effectif des pathologies rares (21).
- MNM et SLA réunies dans le même groupe
- le mode d'évaluation a été précisé (double processus)
- Unité élémentaire constitutive : Health Care Provider
- chaque HCP devra candidater à titre individuel
- filtre / évaluation préalable
 - par les autorités nationales (chez nous, DGOS)
 - assistée (?) par les Filières (quand elles existent)
- en parallèle, l'ERN devra candidater en tant que tel
- Newcastle se positionne comme leader naturel et légitime
- les ERN auront une existence juridique (legal entity)

How can you get involved in building a Network?

As healthcare professionals and providers, experts, patients and authorities, you should reflect on which diseases or conditions in your area of expertise would match the criteria of rarity or low prevalence and complexity, as set out in the legislation governing ERNs. And focus on the grouping of diseases and the types of services to be offered.

Then you can use your experience to examine the technical and organisational feasibility of the Network. You can bring in existing networks, specialised centres, or scientific associations to do this. The ERNs are based on a cooperative, multidisciplinary approach, so you should also look to develop the right forum to move the project forward.

Who can join a Network?

All the members in a Network should have in common the same area of expertise and focus on the same health condition(s).

All Networks should demonstrate that they are strong in:

- · patient empowerment and patient-centred care;
- organisational, management and business continuity of the centre of expertise;
- · research and training capacity;
- · exchange of expertise, information systems and e-health tools; and
- good practice, quality, patient safety and evaluation.

For more information on the application process and requirements, please visit ec.europa.eu/join-ern



What are European Reference Networks?

Imagine if the **best specialists** from across Europe could join their efforts to tackle **complex or rare medical conditions** that require **highly specialised healthcare** and a concentration of knowledge and resources.

That's the purpose of **the European Reference Networks** and it's becoming a reality.

Share and enhance your expertise. Talk with your colleagues. Be ready to prepare a proposal and join a network. The European Commission will launch a call for Networks in 2016.

European Reference Networks (ERNs), which are expected to be operational by 2016, will bring together highly specialised healthcare providers from different EU Member States in areas where expertise is rare.

By pooling knowledge and expertise across the EU, they will facilitate access to diagnosis, treatment and provision of affordable, high-quality and cost-effective healthcare in these areas. ERNs will also serve as focal points for medical training and research, information dissemination and healthcare evaluation.

The intention is not to create new providers, but rather to link existing highly specialised providers.

CHALLENGES

- To engage, attract, identify the right Networks and healthcare providers
- To establish a Network model with useful platforms and tools
- To foster commitment by Member States and ensure sustainability of established Networks
- To avoid fragmentation and/or duplication of efforts
- To develop and use standardised tools (clinical guidelines, registries, patient pathways, interoperable IT systems)
- To involve healthcare professionals, health authorities, managers and patients in a common project for the implementation of ERNs

Why are European Reference Networks needed?

It is often difficult for the 28 health systems of the EU to provide patients with rare or low prevalence complex diseases or conditions with the treatment they need. Therefore the European institutions and the Member States, have decided to implement ERNs to help address this difficulty.

The aim is to benefit patients by improving high-quality specialised care, through better co-operation and greater economies of scale.


BENEFITS

- Improve high-quality specialised care, for patients with rare or low prevalence complex diseases or conditions
- Improve European cooperation and economy of scale on highly specialised healthcare
- Pool knowledge on certain diseases or treatments
- Improve diagnosis and treatment capacities where expertise is rare by developing and sharing clinical guidelines and patient pathways
- Help Member States enhance the provision of highly specialised care
- Maximise the speed and scale of incorporating innovation in medical science and health technologies
- Serve as focal points for medical training and research

There are also obvious benefits to health systems, in improving and optimising their ability to provide such highly specialised care.

There will be other benefits as well. The pooling of knowledge and expertise will allow for the development of more evidence-based clinical tools and treatment. Networks should help maximise the speed and scale at which innovation in medical science and health technologies is incorporated into healthcare provision. They will serve as focal points for medical training and research and for the dissemination of information to other parts of the health system. And they will offer capacity for translational research, clinical trials, Health Technology Assessments, and more.

The providers involved in the Networks will obviously benefit from this pooling of knowledge with other specialists and will be recognised as leaders in their area of expertise.



A model for the purposes of grouping RD thematically

Rare immunological and auto-inflammatory diseases

Rare bone diseases

Rare cancers* and tumours

Rare cardiac diseases

Rare connective tissue and musculoskeletal diseases

Rare malformations and developmental anomalies and rare intellectual disabilities

Rare endocrine diseases

Rare eye diseases

Rare gastrointestinal diseases

Rare gynaecological and obstetric diseases

Rare haematological diseases



Rare craniofacial anomalies and ENT disorders
Rare hepatic diseases
Rare hereditary metabolic disorders
Rare multi-systemic vascular diseases
Rare neurological diseases
Rare neuromuscular diseases
Rare pulmonary diseases
Rare renal diseases
Rare skin disorders
Rare urogenital diseases

*Note: The networking of rare cancers is currently under discussion in EC Expert Group on Cancer Control.




Filnemus Filière Neuromusculaire 2ÈME JOURNÉE DE FILNEMUS 6 NOVEMBRE 2015

Les incertitudes

- modalités de la gouvernance / désignation du coordinateur
- taille minimale connue (8 pays 10 centres) quid de taille optimale réseau ?
- critères objectifs pour être HCP éligible
 - où mettra-t-on le curseur ? qui le mettra ?
 - réseau avec 1 ou 2 centres experts de taille critique et multivalent vs. modèle FSMR
- financement des actions
 - uniquement pour de la coordination ?
- place des Filières (ici, Filnemus)
 - acteur collatéral ou à part entière ?
- calendrier de mise en place
- services et valeur ajoutée attendus
 - orientation soins +++
 - mais lien aussi avec recherche translationnelle

Structure




Governance HC prov 1 2 HC prov 3 3

ISSUES:

- ✓ Where are patients representatives going to be represented? At a country level? At an European Level?
- ✓ How many HC providers are there going to be in the ERN? Depending on this number; the Board of the ERN could become non governable.
- √ How is the Coordinator going to be nominated?

Possible working Groups that could feed into the Board of the ERN



Board of the ERN should be supported by:

Among others Grant Search for sustainability Contacts with Industry **Ethics Committe** Secretariat External evaluation body **Educational Board** Research Board Input about the teaching priorities Input on common research priorities Evaluation of the initiatives Screening of research projects Grant applications for research

ERN tentative timeline & milestones



May 2014

July 2014

II quarter 2015

IV quarter 2015 II quarter 2016











Entry into force legal acts

Call for Assessment Manual

Call for selection independent body(ies)

Call for Networks

Establishment of Networks















Points d'attention



- leadership de Newcastle
 - légitimité indiscutable
 - workshop fondateur ENMC de 2013
 - le bilan du TREAT-NMD
 - l'implication dans le comité EUCERD
- Nécessité de peser dans la future gouvernance de l'ERN
 - soit au travers d'un représentant national (à désigner par FILNEMUS)
 - soit en prenant le lead sur des thématiques / WP
 - formation enseignement
 - accompagnement
 - essais thérapeutiques
 - imagerie...
- que restera-t-il du Treat-NMD ?
- Quid si brexit ?
- la place des 'petits' Etats-Membres




















Care and trial site registry



for animal assessment









2007-2011 EU funded Network

2012 onwards

Alliance funded through multiple streams with global partners & membership

Governance

Chair – Annemieke Aartsma-Rus Vice Chair – Eric Hoffman

Executive Committee

Supported by academic advisory board ("task force") of NMD leaders

Total of 360 members

100 organizations – 40 countries

260 individuals – 42 countries

Members in every continent apart from Africa 🕾




A FAIRE



- poursuivre la réflexion de manière collégiale
- y compris avec nos propres administrations hospitalières
- l'enrichir de celles des autres FSMR
- la partager avec les collègues européens
 - NL, D, Dk, Espagne, et autres
- identifier les expertises françaises
 - dans les réseaux par maladies
 - Steinert, Laminopathies, Pompe...et bien d'autres
 - par thématique (plus facile, cf. commissions FILNEMUS)
- but : arriver en position de force au workshop de Newcastle
- être force de propositions (alternatives)

Rare Neuromuscular Diseases ERN **Areas of interest – How to map different participants?**



Contact 1 or more experts in the different areas, cascade the information through those experts

Establish the connection between the different centres. Involve patient organizations Establish the aims, structure, governance, services to be offered, integration

of existing networks (most of them research based networks)

COUNTRIES ENGAGED

Netherlands

Germany

Cyprus

Spain

France

Belgium

Hungary

Sweden

annexes

Networks criteria and capacities (From the Delegating and Implementing acts):

- Knowledge and expertise to diagnose, follow up and manage patients
- Evidence of good outcomes
- Multi-disciplinary approach
- Capacity to produce and implement: good practice guidelines, outcome measures and quality control
- Research, teaching and training
- Collaborate with other centres of expertise and networks

How to prove this?



Current status of specialized neuromuscular centres in Europe

Experience in the neuromuscular field on networking activities and Biobanks:

European Neuromuscular Centre (ENMC)

TREAT-NMD Alliance

Telethon Network of Genetic Biobanks (TNGB) and/or the EuroBioBank (EBB)

RD-Connect

The role of the learned societies in an ERN:

Current resources, such as e-learning, teaching courses and guidelines should be integrated into a future ERN.

Contribute to the establishment of a European NM curriculum and to the structure of the European Board Examination.

e-health:

E-learning programmes are in place through the scientific societies, can be adjusted to different needs.

Other resources are being assembled through projects like the cross border EU project SIGN (telegenetics system to perform genetic counselling and clinical genetics consultations)

Common purpose

 Improve quality and equity of healthcare for patients with NMDs

Equity in diagnostic

Uniform care standards

- Enable exchange of knowledge (teaching and training)
- Help with translational research: the development of new drugs and the recruitment into clinical trials – link to research

Main functions of the ERN

- Promote and sustain good practice
- Organise and manage all relevant information/data
- Help to diffuse valid information to patients, other healthcare providers and the public
- Teleconsultation/Tele expertise
- Training and teaching

Rare Neuromuscular Diseases ERN Services To Be Offered

Still under discussion at the EC level, it is likely that the themes will include:

- healthcare in a network environment,
- clinical guidelines development,
- training
- provision of a better environment for clinical research including clinical trials



What Services should we offer?

Clinical

Direct: teleconsultation, ?traditional clinical appt?

Support to healthcare providers: e-Health

(Exchange, gather and disseminate knowledge)

Non Clinical

Clinical guidelines / patient pathways

(Implement outcome and performance indicators)

Epidemiological surveillance, registries

Training and continuous education programmes

Dissemination of information

Trials

Selection of patients (registries)

Training of professionals in assessment protocols

INCOME AND NON-MONETARY RESOURCES

- The ERN needs to take into consideration:
 - Cross-country payments
 - >IT platform maintenance
 - > Technical support
 - > Administrative work
 - ➤ Network meetings
 - > Dissemination costs
 - Care coordination



ERN IMPLEMENTATION: the way forward

Cross-sectorial cooperation and funding sources

- ✓ Public health program 2014-2020: studies & project grants to approved ERN
- ✓ RTD horizon 2020 : 2016 research on networks organizational models
- ✓ Connecting European Facilities (CEF): the eHealth dimension
- ✓ <u>Structural funds</u> (cross border cooperation)
- ✓ <u>Social funds</u> (training and better skills)





Preparatory and strategic activities From Enrique Terol presentation

Strengthening the network value and capacities:

and Identify Multidisciplinarity
Avoid fragmentation: Grouping of diseases
Identify mature and clear EU added value type of diseases
Discuss y other players, partners and members

- Liaison with MS authorities
- Define the services of the Network
- Agree on the specific criteria for each area of expertise
- Self-assessment exercise (Network and members): decision of participation as members or as Associated National Centres
- Define Pathways models, referral criteria, clinical decision tools
- Information system/indicators